Navidea Biopharmaceuticals Announces Centers for Medicare & Medicaid Services (CMS) Issuance of Lymphoseek® Reimbursement Pass-Through C Code, Effective as of October 1, 2013 Aug 20, 2013
Navidea Biopharmaceuticals to Announce Second Quarter 2013 Financial Results Pre-market on Wednesday, August 7, 2013 Jul 25, 2013
Navidea Biopharmaceuticals Highlights New Data for NAV4694 PET β-Amyloid Imaging Agent Presented at AAIC 2013 Jul 22, 2013
Navidea Biopharmaceuticals’ NAV4694 β-Amyloid Imaging Agent to Be Used in Alzheimer’s Disease Studies by Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) Jul 16, 2013
Navidea Biopharmaceuticals to Co-Sponsor Alzheimer’s Imaging Consortium at Alzheimer’s Association International Conference Jul 11, 2013
Navidea Biopharmaceuticals Initiates Enrollment in Global Phase 3 Trial of NAV4694 PET Imaging Agent Jun 27, 2013
